Dyne Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.54 Insider Own1.00% Shs Outstand51.68M Perf Week9.00%
Market Cap608.25M Forward P/E- EPS next Y-3.74 Insider Trans-2.29% Shs Float50.97M Perf Month16.98%
Income-182.30M PEG- EPS next Q-0.92 Inst Own- Short Float1.72% Perf Quarter114.87%
Sales- P/S- EPS this Y-122.50% Inst Trans1.69% Short Ratio4.42 Perf Half Y72.02%
Book/sh5.55 P/B2.16 EPS next Y-11.50% ROA-45.00% Target Price24.83 Perf Year-30.81%
Cash/sh5.75 P/C2.08 EPS next 5Y- ROE-51.90% 52W Range4.30 - 17.89 Perf YTD0.84%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-32.98% Beta-
Dividend %- Quick Ratio11.60 Sales past 5Y- Gross Margin- 52W Low178.84% ATR0.82
Employees108 Current Ratio11.60 Sales Q/Q- Oper. Margin- RSI (14)67.09 Volatility7.06% 7.97%
OptionableYes Debt/Eq0.00 EPS Q/Q-73.00% Profit Margin- Rel Volume1.80 Prev Close12.05
ShortableYes LT Debt/Eq0.00 EarningsAug 04 BMO Payout- Avg Volume198.35K Price11.99
Recom1.70 SMA209.10% SMA5042.14% SMA20026.34% Volume356,833 Change-0.50%
Jul-20-22Initiated Chardan Capital Markets Buy $17
Jul-12-22Initiated Raymond James Outperform $15
Oct-12-20Initiated Stifel Buy $29
Oct-12-20Initiated Piper Sandler Overweight $34
Oct-12-20Initiated JP Morgan Overweight $27
Oct-12-20Initiated Jefferies Buy $47
Aug-10-22 07:30AM  
Aug-04-22 07:30AM  
Jul-18-22 10:00AM  
Jul-12-22 02:54PM  
Jul-05-22 07:30AM  
Jul-01-22 06:58AM  
Jun-03-22 07:30AM  
May-16-22 07:30AM  
May-02-22 04:05PM  
Mar-17-22 08:45AM  
Mar-10-22 07:30AM  
Mar-03-22 07:30AM  
Feb-02-22 01:38PM  
Jan-22-22 08:06AM  
Jan-18-22 04:18PM  
Jan-05-22 07:30AM  
Dec-03-21 03:30PM  
Dec-02-21 08:30AM  
Nov-04-21 07:30AM  
Oct-26-21 10:41AM  
Oct-13-21 07:45AM  
Oct-01-21 10:21AM  
Sep-28-21 07:30AM  
Sep-27-21 07:30AM  
Sep-20-21 07:30AM  
Aug-05-21 07:30AM  
Jul-26-21 03:00AM  
Jun-25-21 07:30AM  
Jun-02-21 04:05PM  
May-26-21 07:30AM  
May-14-21 02:44PM  
May-06-21 07:29AM  
Apr-27-21 04:35PM  
Mar-04-21 07:35AM  
Feb-08-21 07:30AM  
Jan-27-21 01:13AM  
Jan-20-21 08:05PM  
Jan-10-21 03:00PM  
Jan-05-21 07:30AM  
Dec-08-20 10:17AM  
Nov-09-20 07:30AM  
Nov-05-20 07:35AM  
Oct-09-20 03:41PM  
Sep-21-20 04:05PM  
Sep-16-20 07:00PM  
Dec-13-19 03:38PM  
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scalzo Richard WilliamSee RemarksMar 11Sale8.733082,68926,994Mar 14 05:09 PM
HIGH SUSANNA GATTIChief Operating OfficerMar 11Sale8.737656,67873,003Mar 14 05:08 PM
McNeill JonathanSee RemarksMar 11Sale8.734814,19960,466Mar 14 05:09 PM
Brumm Joshua TSee RemarksMar 11Sale8.733,38429,542210,324Mar 14 05:07 PM
Farwell WildonChief Medical OfficerMar 11Sale8.736405,58766,050Mar 14 05:08 PM
Beskrovnaya OxanaChief Scientific OfficerMar 11Sale8.736936,05053,676Mar 14 05:06 PM
Farwell WildonChief Medical OfficerMar 02Sale8.565,61748,08266,690Mar 03 07:22 PM
HIGH SUSANNA GATTIChief Operating OfficerSep 23Sale17.222,45142,20633,453Sep 24 10:50 AM
McNeill JonathanSee RemarksSep 21Sale16.1172911,74435,636Sep 22 08:02 PM
Brumm Joshua TSee RemarksSep 21Sale16.114,58473,84899,018Sep 22 08:02 PM
Beskrovnaya OxanaChief Scientific OfficerSep 21Sale16.1182713,32317,845Sep 22 08:01 PM
Scalzo Richard WilliamSee RemarksSep 21Sale16.114927,92610,606Sep 22 08:03 PM
Scalzo Richard WilliamSee RemarksSep 20Sale15.613675,72911,098Sep 22 08:03 PM
Beskrovnaya OxanaChief Scientific OfficerSep 20Sale15.616179,63118,672Sep 22 08:01 PM
Brumm Joshua TSee RemarksSep 20Sale15.613,42553,464103,602Sep 22 08:02 PM
McNeill JonathanSee RemarksSep 20Sale15.615458,50736,365Sep 22 08:02 PM